Demographic features of neuroblastoma in Iraq-Kurdistan Region- Sulaimani

Basil K. Abdallah, Nawshirwan Gafoor Rashid¹, Shwan Ali Tawfiq¹

Abstract:

BACKGROUND: Neuroblastoma is the third most common cancer in pediatric age group; it is the most common malignancy in the 1st year of life. The majority of the patients (50%–65%) have advanced disease at diagnosis. Diagnoses, staging investigations, and risk categorization have a great success in neuroblastoma, trying to classify the patient into risk groups according to the age, stage, and molecular study and this in turn has important value in the treatment strategies. Despite of this improvement in the early diagnosis and treatment protocol, neuroblastoma stills is one of the malignant diseases that are associated with high morbidity and mortality.

OBJECTIVES: The aims of this study were to evaluate the pattern of presentation, studying the correlation between age, sex, and site of primary tumor with disease staging in patients with neuroblastoma.

PATIENTS AND METHODS: This study was done prospectively over a period of 6 years from February 2008 to February 2014. Sixty-two patients with newly diagnosed pediatric neuroblastoma admitted to Hiwa Hematology/Oncology hospital were included in this study. Age, sex, clinical patterns, staging, and important laboratory findings were assessed. The patients staged according to the International Neuroblastoma Staging System. We divided our patients into three groups according to the risk categories.

RESULTS: Data analyzed using SPSS-13 and P value obtained by Chi-square test, a median age at diagnosis was about 24 months with male predominance. Most common site of the primary tumor was the abdomen; approximately 69% of our patients with neuroblastoma studied were Stage 4.

CONCLUSION: The stage in our study was age dependent, but it was neither depending on the sex nor the site of the primary tumor.

Keywords:

Neuroblastoma, risk groups, sex distribution

Introduction

Neuroblastoma is the most common extracranial solid tumor in infancy. It is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). In the developing embryo, these cells invaginate, migrate along the neuraxis, and populate the sympathetic ganglia, adrenal medulla, and other sites. The pattern of distribution of these cells correlates with the sites of primary disease presentation.¹

Age, stage, and biological features encountered in tumor cells are important prognostic factors and are used for risk stratification and treatment assignment.²,³ The differences in outcome for patients with neuroblastoma are striking. Patients with low-risk and intermediate-risk neuroblastoma have excellent prognosis and outcome. However, those with high-risk disease continue to have very poor outcomes despite intensive therapy. Unfortunately,
approximately 70%–80% of patients older than 18 months present with metastatic disease, usually in the lymph nodes, liver, bone, and bone marrow. Less than half of these patients are cured, even with the use of high-dose therapy followed by autologous bone marrow or stem cell rescue.\textsuperscript{[1,4,5]} The aims of this 6-year prospective study were to evaluate the pattern of presentation, studying the correlation between age, sex, and site of primary tumor with the stage of disease in patients with neuroblastoma.

**Patients and Methods**

Sixty-two patients with newly diagnosed pediatric neuroblastoma admitted to Hiwa Hematology/Oncology hospital in the Sulaimaniya province of Iraqi Kurdistan were included in this study; informed consent was taken from all patients’ parents and permission was taken from ethical committee; they were studied prospectively from February 2008 to February 2014.

**Inclusion criteria**
1. All children aged 15 years or younger
2. Both male and female
3. Histopathologically proved neuroblastoma made either by A or B
   A. From tumor tissue by light microscopy (with or without immunohistology) and/or increased urine catecholamines
   B. Bone marrow aspirate or trephine biopsy contains tumor cell and increased urine catecholamines
4. Newly diagnosed patients who were not treated previously by chemotherapy.

**Exclusion criteria**
1. Age more than 15 years
2. Relapsed neuroblastoma or previously treated with chemotherapy.

Study requirements included all the targeted patients who had their Sulaimani facilities of histopathological diagnosis, complete blood count, liver function test, renal function test, serum electrolyte, serum lactate dehydrogenase (LDH), serum ferritin level, abdominal U/S, chest X-ray, computed tomography-scan, and/or magnetic resonance imaging of the primary site, chest and abdomen and bone marrow aspirate and trephine biopsy. Limitation include molecular studies, namely Nmyc study MIBG and positron emission tomography scan were not available. The patients were staged according to the International Neuroblastoma Staging System, then the patients were divided into low, intermediate, and high-risk groups according to the children oncology group.

**Statistical analysis**
Data were analyzed using SPSS software, version 13 (IBM company, USA), and $P$ value was obtained by Chi-square test. $P < 0.05$ was considered as statistically significant.

**Results**

Among 62 patients with neuroblastoma studied, 37 patients (59.677%) were male and 25 patients (40.323%) were female. The male: female ratio was 1.48:1. Figure 1 shows the sex distribution.

A median age at diagnosis was about 24 months with peak age of incidence between 1 and 5 years. Table 1 shows the number and percentage of the cases in relation to the age.

The most common site of the primary tumor was the abdomen which was the primary site of the tumor in 41 out of 62 patients (66.12%), followed by thoracic primary which occurred in 11 patients (17.74%), paraspinal primary in 4 patients (6.45%), cervical primary occurred in 4 patients (6.45%), and head primary which was happened in 2 patients (3.22%) [Figure 2].

Figure 2 shows the percentage of the patients in relation to the site of the primary tumor.

Among the 62 patients with neuroblastoma studied, 43 patients (69.35%) were Stage 4, 8 patients (12.9%) were Stage 4S, 7 patients (11.29%) were Stage 3, 3 patients (4.83%) were Stage, 2 and 1 patient (1.61%) was Stage 1 [Figure 3].

Our study showed that there is significant correlation between age and staging with localized disease; Stage 1 and 2 occurred more in younger age and advanced stage, i.e., Stage 3 and 4 found in older children.

Table 2 shows the relation between age and the stage. Table 3 shows the relation between sex of the patients with their stages & were statistically not significant ($P = 0.809$).

| Age (years) | Number of patients (%) |
|------------|------------------------|
| <1         | 19 (30.64)             |
| 1-5        | 31 (50)                |
| 6-10       | 10 (16.12)             |
| 11-15      | 2 (3.22)               |

Figure 1: Sex distribution of paraspinal neuroblastoma
Chi-square test showed that the difference among the stages and the age was statistically significant ($P$ value = 0.049).

The relation between the primary site of the tumor and staging is shown in Table 4 ($P = 0.897$).

Among the 62 patients with neuroblastoma (NBL) studied, 34 patients (54.84%) were high-risk group, 17 patients (27.42%) were intermediate-risk group, and 11 patients (17.74%) were low-risk group.

Figure 4 shows the number of patients according to the risk categories of NBL.

**Discussion**

The total number of cases studied was sixty-two, over a period of 6 years.

We found that males were affected more than females with male:female ratio being 1.48:1; this ratio is higher than male:female ratio in most large studies which was 1:1:1.\(^1\) It is also higher than the male:female ratio in USA which was 1.2:1.\(^6\)

Peak age of incidence at presentation in our study was 1–5 years which was comprise (50%); this was similar with the result of cooperative group studies at Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) institution from 1986 to 2001 which also showed peak age incidence between 1 and 5 years.

A median age at diagnosis was about 24 months in our study which is higher than that showed at POG and CCG institution from 1986 to 2001 which was of about 19 months.\(^1\)

This higher median age at diagnosis in our study might result from possibly delayed diagnosis of the disease in our community because of the poor family knowledge regarding the disease and absence of screening program.

The most common site of the primary tumor in this study was the abdomen which represent approximately 66.1% followed by thoracic primary in 17.74%, paraspinal

---

**Table 2: Staging in relation to age ($P=0.049$)**

| Age (years) | Stage 1, $n$ (%) | Stage 2, $n$ (%) | Stage 3, $n$ (%) | Stage 4, $n$ (%) | Stage 4S, $n$ (%) | Total, $n$ (%) |
|------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|
| <1 year    | 1 (5.26)        | 1 (5.26)        | 3 (15.78)       | 8 (42.10)       | 6 (31.57)       | 19 (100)       |
| 1-5 years  | 0               | 2 (6.45)        | 3 (9.67)        | 26 (83.87)      | -               | 31 (100)       |
| 6-10 years | 0               | 0               | 1 (10)          | 9 (90)          | -               | 10 (100)       |
| 11-15 years| 0               | 0               | 0               | 2 (100)         | -               | 2 (100)        |

*From the definition of stage 4S, it just occurs in infancy

**Table 3: Sex in relation to the stage ($P=0.809$)**

| Stage | Male | Female |
|-------|------|--------|
| Stage 1 | 0/37 | 1/25 (4) |
| Stage 2 | 2/37 (5.4) | 1/25 (4) |
| Stage 3 | 4/37 (10.81) | 3/25 (12) |
| Stage 4 | 26/37 (70.27) | 17/25 (28) |
| Stage 4S | 5/37 (13.51) | 3/25 (12) |

---

**Figure 2: Site of primary tumor (percentage)**

**Figure 3: Stage distribution of paraspinal neuroblastoma**

**Figure 4: Number of patients according to the risk categories of paraspinal neuroblastoma**
primary in 6.45%, cervical primary occurred in 6.45%, and head primary which was happened in 3.22%.

According to the international figure, abdominal primary was also the most common site at presentation and it was seen in 65%.[1,7]

The majority of the patients had advanced disease at the time of diagnosis, approximately 69.35% of the patients had Stage 4 at presentation, 12.9% were Stage 4S, 11.29% were Stage 3, 4.83% were Stage 2, and only 1.61% was Stage 1. This result means that our patient is more likely to have advanced stage (Stage 3 and 4) than those observed in the international figure (50%–60% of all neuroblastoma cases present with metastases).[1,8]

This higher percentage of advanced disease at diagnosis might be due to delayed medical care and absence of screening program.

We also discovered that there is a strong correlation between age and staging as the proportion of patients presenting with localized, regional, or metastatic disease is age dependent. Localized disease (Stage 1 and 2) occurred more in younger age and advanced stage (Stage 3 and 4) was found in older children. This result is again similar to the international figure.[1,9,10]

In our study, we found no correlation between sex and the stage of neuroblastoma at the time of diagnosis.

Furthermore, there was no relation between the primary site of neuroblastoma and stage of the disease.

Most of the patients were classified as high-risk group (54.84%), followed by the intermediate-risk group (27.42%) and only 17.74% were low-risk group; we did not include serum LDH and ferritin in our analysis to avoid further expansion of our study.

Conclusion

Neuroblastoma was higher in males than females in our community. Peak age group was 1–5 years; a median age at diagnosis was about 24 months. It is extremely rare after the age of 10 years, and the majority of the patients presented with abdominal primary at the time of diagnosis.

Most of the patients had distant metastases at presentation (Stage 4 disease).

There was strong correlation between age and advanced stage which meant that the stage is age dependent. Neither there was relation between the primary site of the tumor and the stage nor significant correlation between the sex of the patients and the stage.

Despite the absence of MIBG, bone scan, cellular, and molecular study for proposed risk stratification system for purpose of risk categories, 54.84% of our patients got high-risk category.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Pizzo PA, Poplack DG. Principle and Practice of Pediatric Oncology. 5th ed., Ch. 31. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 934-70.
2. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, et al. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the pediatric oncology group. Cancer 1992;69:2197-211.
3. Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric oncology group study. J Natl Cancer Inst 1997;89:373-80.
4. Lanzkowsky P. Manual of Pediatric Hematology and Oncology. 5th ed., Ch. 22. USA: Academic Press; 2011. p. 671-94.
5. Rothenberg AB, Berdon WE, D’Angio GJ, Yamashiro DJ, Cowles RA. Neuroblastoma—remembering the three physicians who described it a century ago: James homer wright, William pepper, and Robert Hutchison. Pediatr Radiol 2009;39:155-60.
6. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the pediatric oncology group. Cancer 1993;71:3173-81.
7. Friedman GK, Castleberry RP. Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer
8. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children’s oncology group study. J Clin Oncol 2009;27:1007-13.

9. Robert S, Primo N, Timothy C, Amy H, Kristi D. National Cancer Institution and the National Institute of Health. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/page3#Section-185.

10. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, ChenHX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.